BioSpace News Archive

Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it has received FDA approval of two pivotal investigational device exemptions (IDE) for its Exablate Neuro system – one for primary non-small cell lung cancer (NSCLC) that has metastasized to the brain in conjunction with standard-of-care Keytruda®.

Monoclonal antibodies have been discovered by leading medical companies, startups, and researchers at universities as a treatment option for different types of conditions.

In the last few years, there’s been an increasing demand for economical and disposable medical device packaging solutions in the majority of countries, which has acted as the major factor driving the growth of the global medical device packaging market.

Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, announced today that it has been awarded a $1.7 Million Small Business Innovation Research (SBIR) Phase II grant from the National Institute of General Medical Sciences.

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in March:.

A real-time electronic decision support system helped clinicians at community hospitals provide best practice care for emergency department patients with pneumonia, resulting in decreased intensive care unit admission, more appropriate antibiotic use, and 38% lower overall mortality according to a new study by researchers at Intermountain Healthcare in Salt Lake City.

RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Barclays Global Healthcare Conference 2022.

BioSyent Inc. released its financial results for the three and twelve months ended December 31, 2021.

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its fourth quarter and full year financial results for the full year 2021.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky will present in-person at the Barclays Global Healthcare Conference on March 15, 2022 at 10:45 a.m., EST.